Order from us for quality, customized work in due time of your choice.
Thalidomide was first licensed in July 1956, intended as sedative, treats many conditions. Initially it was considered safe for pregnant women. Caused significant developmental issues in babies. 1961: withdrawn after a major scandal. Thalidomide was greatly affected drug testing and approval.
Birth defects if taken during pregnancy
-
Can also be transmitted by semen.
-
Defects include amelia, phocomelia, facial palsy.
-
absense of bones, and heart defects.
-
Thromboembolism in combination with other drugs.
-
Temporary or permanent nerve damage.
Side effects similar to other tranquilizers
-
Neurological: Somnolence, fatigue, weakness, mood alteration.
-
Neurological: mild tremors, ataxia, anxiety and confusion.
-
Gastrologic complications: constipation to toxic megacolon.
-
Cardiovascular: hypertension, bradycardia, and peripheral edema.
-
Hematologic: neutropenia, hypochromic anemia, splenomegaly, thrombocytopenia.
-
Used to treat leprosy and cancer.
Hypotheses for the mechanism for teratogenicity
-
Anti-angiogenesis and oxidative stress models.
-
Hypotheses for immunomodularity and anti-inflammatory effects.
-
Modulation of tumor necrosis factor alpha.
-
Suppression of macrophage involvement of prostaglandin synthesis.
References
Ghobrial, I. M., & Rajkumar, S. V. (2003). Management of thalidomide toxicity. The Journal of Supportive Oncology, 1(3), 194-205.
Ito, T., & Handa, H. (2012). Deciphering the mystery of thalidomide teratogenicity. Congenital Anomalies, 52(1), 1-7.
National Center for Biotechnology Information (2021). PubChem Annotation Record for THALIDOMIDE.Â
Science Museum (2019). Thalidomide.Â
Order from us for quality, customized work in due time of your choice.